Alemtuzumab is a humanized monoclonal antibody targeting CD52, used to treat chronic lymphocytic leukemia and multiple sclerosis by depleting circulating lymphocytes. It is grouped under the following drug class(es): Monoclonal antibodies. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include LDP-03, Monoclonal Antibody Campath-1H and MabCampath. Its PubChem SID is 481101485.
Alemtuzumab
| CAS No | 216503-57-0 |
|---|---|
| Molecular Formula | N/A |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Alemtuzumab is a humanized monoclonal antibody targeting CD52, used to treat chronic lymphocytic leukemia and multiple sclerosis by depleting circulating lymphocytes.
The listed CAS number is 216503-57-0.
The listed molecular formula is N/A.
N/A.
The source lists LDP-03, Monoclonal Antibody Campath-1H and MabCampath.
Its therapeutic use is listed as multiple sclerosis agents.